Dosage Forms

A biosimilar to Eli Lilly’s Forsteo, biosimilar teriparatide, has been launched across Europe by Gedeon Richter following the patent expiration of the reference product.

Marchesini Group’s Compact 12 electronic counter with HarleNIR vision system measures product and active ingredient when filling and capping bottles for tablets and capsules.

Regulatory, cultural, and technical differences between drug and device development can pose challenges to pharmaceutical combination product development.

The latest research from GlobalData has revealed that more than two-thirds (69%) of CMOs high-containment facilities are based in the top five European Union countries and Switzerland.

The European Commission has approved an extension of the use of Dupixent (dupilumab) within the EU to include patients aged 12 to 17 years old with moderate-to-severe atopic dermatitis.

Homogeneity of the powder blend is crucial for solid-dosage drug manufacturing.

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.

Glass vials have come a long way from mere commodities and are now considered an integral part of final drug product.

Formulators of parenteral drugs must be cautious of specific considerations and challenges that arise during development and manufacture.

As patient-centered therapies and clinical trials become more important, innovation is providing more control and transparency in the way that pharmaceuticals are delivered.

Industry experts discuss the role of gene-editing techniques in regenerative medicine and cell-line development.

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.

Researchers in China are playing a role in advancing gene therapy development.

Daiichi Sankyo Europe has revealed the results of a Phase III study assessing the efficacy, safety, and tolerability of bempedoic acid/ezetimibe fixed-dose combination (FDC) tablet.

Neuraxpharm Group has announced it is launching its first products in the United Kingdom.

Iontas and Teva Pharmaceuticals have entered into an agreement for the application of technologies and know-how into the optimization of human antibodies to be used as biotherapeutics.

Cure Pharmaceutical secured a patent that lets the company load higher drug amounts to its proprietary drug delivery system, CUREfilm.

Lonza plans to implement MES software to accelerate paperless, 24/7 production of drug capsules.

Suheung’s new facility in Vietnam is dedicated to vegetarian capsule manufacturing.

An agreement with Sanofi gives Catalent access to commercial spray drying facility in Haverhill, UK.

Several trends are driving change in oral solid‑dosage forms and giving rise to the requirement of ‘fit-for-purpose’ excipients.

More than 30 lots of losartan drug products have been recalled due to contaminated API manufactured by Hetero Labs.

Novavax will sell two Maryland-based vaccine development and manufacturing facilities for Catalent’s expanding gene therapy footprint.

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.